1412. Vitamin D: The “feel-better” drug for Clostridium difficile infection?
Session: Poster Abstract Session: Clostridium difficile
Saturday, October 5, 2013
Room: The Moscone Center: Poster Hall C
  • CDiff IDWeek Poster Final Revision Ken-Rebecca.pdf (233.2 kB)
  • Background: Clostridium difficile infection (CDI) is among the leading cause of hospital acquired infections and has a significant burden on the healthcare system. It has been reported that Vitamin D-deficient patients with CDI have 5-fold higher healthcare-associated expenses and a length of stay 4 times longer than their non-deficient counterparts. Accordingly, the objective of our study was to evaluate the relationship between Vitamin D level and recurrence, CDI severity, mortality and the course of Clostridium difficile-associated diarrhea (CDAD).

    Methods: An IRB-approved retrospective chart review of 2097 adult patients admitted to a community teaching hospital with diagnosis of CDI during a recent five-year period was conducted. One hundred twelve patients had a 25(OH) Vitamin D level drawn within 3 months of their CDI diagnosis and were included in the study. Recurrence, severity of disease, 30-day mortality and the course of CDAD were assessed. Chi-square test was utilized for categorical variables and t-test for continuous variables, and any differences with a p value <0.05 was considered statistically significant.

    Results: 25(OH) Vitamin D less than 20 was considered as Vitamin D deficient. There were 56 patients in the Vitamin D-deficient group and 56 patients in the normal group. The mean age of Vitamin D-deficient and -sufficient groups were 68±15.7 and 71±14.4 years, respectively.  The mean 25(OH) Vitamin D level in the deficient group was 11.7±4.6 ng/mL, and 36.2±36.2 ng/mL in the normal group (p<0.05). A longer course of diarrhea was apparent in the Vitamin D- deficient group compared to the normal group (5.8 ±4 days vs 4.1 ±2.8 days; p=0.01). The Vitamin D-deficient group also had a higher incidence of sepsis compared to the normal group (42.8% vs 23.2%;p=0.027). However, in this study, there did not appear to be any differences in CDI recurrence, length of stay, severity of illness and mortality with respect to Vitamin D status.

    Conclusion: The results from this study suggest that Vitamin D-deficiency may be related to prolonged course of CDAD. In addition, Vitamin D-deficiency may also result in an increased rate of sepsis in CDI patients. This study is limited by small sample size and therefore future larger-sampled studies will help more clearly to elucidate the relationship between Vitamin D status and the course of CDI.

    Ken Koon Wong, MD, Internal Medicine, Akron General Medical Center, Akron, OH, Rebecca Lee, MD, OB/GYN, Akron General Medical Center, Akron, OH, Richard Watkins, MD, MS, Division of Infectious Diseases, Akron General Medical Center, Akron, OH and Nairmeen Haller, Ph.D, Akron General Medical Center, Akron, OH


    K. K. Wong, None

    R. Lee, None

    R. Watkins, None

    N. Haller, None

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.